AstraZeneca Owes Pfizer $108 Million in Tagrisso Patent Loss (2)

AstraZeneca Plc must pay Pfizer Inc.’s Wyeth unit $107.5 million after a federal jury in Delaware found its blockbuster cancer drug Tagrisso infringes two patents for Pfizer’s competing Vizimpro.

Tagrisso infringes Wyeth LLC’s US Patent Nos. 10,603,314 and 10,596,162, according to a verdict issued Friday in the US District Court for the District of Delaware. Jurors also rejected AstraZeneca’s arguments for voiding the patents. Their finding that the infringement wasn’t intentional spared AstraZenenca the specter that the judge might triple the amount awarded.

AstraZeneca “is disappointed by the jury’s verdict” and is “confident in our IP position in relation ...